MODERNA COVID-19 VACCINE TRIAL REPORTS PROMISING RESULTS
by John G. Baresky on 05/18/20Initial evaluation results of COVID-19 immunization are good
Cambridge, Massachusetts-based Moderna (NASDAQ: MRNA) is the first company to provide Phase 1 clinical trial results of a COVID-19 vaccine candidate. Founded in 2010, Moderna has a contract with the Biomedical Advanced Research and Development Authority (BARDA) to develop and manufacture a SARS-CoV-2 immunization. BARDA is part of the Department of Health and Human Services (HHS). The trial was launched at the Kaiser Permanente Washington Health Research Institute in Seattle.
Key details from the Moderna COVID-19 vaccine trial include:
- The trial patients were males and females ranging in age from 18 to 55 years
- Clinical results indicate the vaccine produced antibodies in 45 out of 45 trial patients
- Three different strengths (25, 100, 250 microgram doses) were featured in the trial and all performed well
- 3 groups of 15 each were administered one of the 3 strengths twice that were spaced 28 days apart
Moderna's proposed COVID-19 vaccine is unique
- The Moderna COVID-19 trial vaccine is based on genetic material called messenger RNA (mRNA) produced in a lab that instructs human cells on what kind of antigen to create that will trigger an immune response to the COVID-19 virus. If the complete results of the Phase I results are satisfactory, the evaluation will progress to a Phase II trial that may encompass approximately 600 adults during this summer.
Comments (0)
